Issue 1891: September 2, 2026

One document puts every available translation of the injectable influenza vaccine VIS at your fingertips as you prepare for influenza vaccination clinics this fall. Be ready to offer influenza vaccine information in their preferred language to almost any client who walks in.

Titled QR Code Links to Vaccine Information Statement (VIS) Translations: Influenza (Flu) Vaccine (Inactivated or Recombinant), this 3-page PDF assembles QR codes for 44 injectable influenza VIS translations. Page one leads off with basic instructions, along with the QR code to the required English VIS and the most popular Spanish VIS. Pages two and three provide the QR codes for each additional language option, along with a few additional VIS resources for healthcare professionals.

Beneath each QR code is the language (in English) and the VIS title in each language. This allows vaccine recipients who do not read English to locate and scan the code for their preferred language with their own smartphone. 

     

This resource does not go out of date. If a VIS is updated, the QR code will automatically link to the current available version online at Immunize.org. Download this resource today as you prepare for influenza vaccination clinics this fall.

Related Links

• Immunize.org: Vaccines A–Z: Influenza web page
• Immunize.org: Clinical Resources A–Z main page, where you can filter by topic, vaccine, language, or other criteria

VISs explain both risks and benefits of vaccination. Federal law requires you to document provision of CDC’s current VIS before administering any vaccine covered by the Vaccine Injury Compensation Program. CDC recommends VISs accompany other vaccines, too. An easy, paperless way to comply with the law is for patients to scan a QR code and access the VIS from a smartphone or tablet. 

These tables belong in any room where vaccinations are given.

Learn more in our 2-minute Laminated VIS QR Code Tables video. The video is available in the Immunize.org shop and on our YouTube channel. 

Pricing (includes all shipping and handling costs)

Visit the Shop Immunize.org: Laminated VIS QR Code Tables web page to view images and order today! For additional information, call 651-647-9009 or email admininfo@immunize.org. 

Immunize.org's www.Give2MenACWY.org website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines, so vaccine outreach is more important than ever.

If you are looking for tools to explain meningococcal vaccine recommendations and assist in improving adolescent coverage for all recommended vaccines, view this site. Check out the many helpful tools from Immunize.org, CDC, and other organizations.

  

The website is divided into five easy-to-access sections:

• Vaccinate Teens: teen vaccination schedules and tips for improving vaccination rates
• Give 2 Doses: tools to help improve second dose coverage of MenACWY vaccine
• 16-Year-Old Visit: resources to help providers and patients remember the important vaccines recommended for 16-year-olds
• Tools for Providers: tools to explain meningococcal ACWY vaccine recommendations and improve coverage for all adolescent vaccines
• Resources: links to print materials, organizations involved in adolescent vaccination, personal stories about the importance of vaccination, and other resources of interest

The site also categorizes materials according to whether they are primarily of interest to providers, to adolescents, or to parents.

Visit Give2MenACWY.org and enjoy browsing (and deploying) its bountiful resources.

Related Links 

• MenACWY: You're Not Done If You Give Just One: Give 2 Doses to Strengthen Protection
• Recommending MenACWY: What to Say and How to Say It
• Top 10 Ways to Improve Adolescent Immunization Rates 
• Developing an Immunization Culture in Your Office 
• Know Your Rates: Measuring Immunization Success in Your Practice
• Immunize.org: You're 16: We Recommend These Vaccines for You
• Dear Colleague Letter: 16-Year-Old Patients: Make Sure They Receive Their Annual Well Visit and Vaccinations, signed by six medical societies
• Immunize.org: Ask the Experts: Meningococcal ACWY 
• CDC: ACIP Meningococcal Vaccine Recommendations
• CDC: Vaccination Coverage Among Adolescents Aged 13–17 Years—National Immunization Survey–Teen, United States, 2024

As RSV season approaches, use of maternal RSV vaccination with Abrysvo (Pfizer) will resume in most of the contiguous United States in September. For those who choose maternal vaccination, a single vaccine dose is recommended during pregnancy between 32 and 36 6/7 weeks’ gestation. Abrysvo is not recommended if the mother has received a previous RSV vaccine dose for any reason. If Abrysvo is not given or if the baby is born less than 14 days after Abrysvo is given, the infant should receive an RSV preventive antibody (nirsevimab [Beyfortus] or clesrovimab [Enflonsia]) for protection. 

In general, the time to administer RSV preventive antibody products to infants younger than 8 months of age begins in October in most areas in the United States, unless otherwise advised by state or territorial public health authorities in response to local RSV activity patterns. All infants younger than 8 months, 0 days, whose mothers were not effectively vaccinated against RSV during pregnancy are eligible.

Preparation should begin now to recall eligible infants born in the spring or summer who will need an RSV preventive antibody product for the coming season. Keep in mind the following:

• Two product options are available for infants younger than age 8 months: nirsevimab (Beyfortus, Sanofi) or clesrovimab (Enflonsia, Merck), given as a single dose.
• Infants younger than age 8 months whose mothers were effectively vaccinated against RSV with Abrysvo during pregnancy or who received a dose of RSV preventive antibody last spring should not be given an RSV preventive antibody now.
• Only Beyfortus is currently recommended for designated children age 8 through 19 months at increased risk for severe RSV in their second RSV season. For specific guidance on high-risk children, refer to the forthcoming American Academy of Pediatrics (AAP) 2026–27 RSV season guidelines anticipated in early September. IZ Express will announce the publication.
• Prepare now for reminders and scheduling of infants born during the spring and summer who are due for RSV preventive antibody in October; evidence from coverage rates last season indicates that these infants are often missed and could benefit from specific outreach.
• An unprotected infant who is not at high risk and turns age 8 months is no longer eligible to receive RSV preventive antibody protection.
• In regions with atypical RSV seasonality, such as Alaska, Hawaii, southern Florida, and certain U.S. territories, RSV activity patterns differ from most of the contiguous United States and those who offer Abrysvo or preventive antibody products should follow the timing recommended by state or local public health officials.

Immunize.org standing order templates for RSV preventive antibody products will be released in September, as soon as feasible following publication of the AAP 2026–27 RSV guidelines. 

Related Links

• ACOG: Maternal Respiratory Syncytial Virus Vaccination Practice Advisory (Updated 10/2025)
• Pediatrics: Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement (10/20/25)
• Immunize.org: Vaccines A–Z: RSV (Respiratory Syncytial Virus) main page

In its August 16 issue, International Journal of Infectious Diseases published HPV Vaccination and Risk of Head and Neck Cancers: A Large Real-World Cohort Study. The team conducted a retrospective cohort study using de-identified electronic medical records from 66 U.S. healthcare organizations. They matched 716,630 HPV-vaccinated individuals (age 9–45 years) one to one with 716,630 non-vaccinated controls based on age, sex, and comorbidities. The conclusions section appears below.

HPV vaccination is associated with a substantially lower risk of HNC [head and neck cancers]–most pronounced for OPSCC [oropharyngeal squamous cell carcinoma] and among younger recipients. These findings suggest that broad HPV immunization coverage may provide potential public health benefits by reducing the risk of HNC.

Currently available online, Vaccine published Heterogeneity Among the Vaccine Hesitant: A Secondary Analysis of the National CEAL Common Survey Data (print publication date October 3, 2026). CEAL refers to the Community Engagement Alliance. Portions of the abstract appear below.

This large national sample included 13,802 participants; 31.30% Non-Hispanic [NH] Black, 36.70% Hispanic, and 27.75% Non-Hispanic White. Over 12% of sample respondents indicated they had not received any dose of the COVID-19 vaccine. NH White participants were most likely to be vaccinated (91.80%), while Non-Hispanic Black participants were least (81.78%). There were significant educational and age gradients related to vaccination; 20.78% of those with high school education were unvaccinated compared to 6.18% of those with a graduate degree. Participants 55 years and older were less likely to be unvaccinated compared to younger participants. Less than 5% of the participants distrusted their doctors in providing COVID-19 information, while approximately over 40% distrusted the FDA to ensure a safe pediatric vaccine. Among the unvaccinated, there were racial and educational differences in reasons for being unvaccinated, such as dislike of needles and belonging to communities that disproved of being vaccinated. Future vaccine campaigns will likely need different approaches to convince population sub-groups to be vaccinated.

Currently available online, Vaccine published Cardiac outcomes following SARS-CoV-2 infection versus BNT162b2 vaccination in adolescents and young adults: a cohort study of 4 million individuals (print publication date October 3, 2026). This retrospective, multicenter cohort study was conducted using de-identified electronic health records from a health research network that includes 70 participating healthcare organizations across the United States. Data was analyzed for 4,072,375 individuals age 16–25 years.
 
The study showed that COVID-19-vaccinated individuals had a lower risk of myocarditis and pericarditis than unvaccinated and naturally infected ones. Portions of the background, findings, and interpretations sections appear below.

We compared risks of myocarditis, pericarditis, and mortality between infection and BNT162b2 vaccination in adolescents and young adults. . . . 

The infected/unvaccinated group had the highest cumulative incidence of myocarditis (0.116%). . . . SARS-CoV-2 infection was associated with significantly higher risks of myocarditis (relative risk [RR] = 4.91; . . . pericarditis (RR = 1.93; . . . and mortality (RR = 1.33; . . . versus no infection. In direct comparison, vaccination was associated with 85% lower myocarditis risk, 79% lower pericarditis risk, and 72% lower mortality versus infection. Protection was consistent across sexes. The absolute risk difference for myocarditis was 0.0354%, corresponding to one fewer recorded myocarditis event per 2827 individuals in the vaccinated/uninfected group compared with the infected/unvaccinated group.

Recorded SARS-CoV-2 infection was associated with higher short-term risks of myocarditis, pericarditis, and all-cause mortality than recorded BNT162b2 vaccination in adolescents and young adults. These findings support a favorable benefit-risk profile for BNT162b2 vaccination relative to documented infection, although the observational all-cause mortality comparison should be interpreted as descriptive rather than causal.

To learn simple tips and tricks for using our affiliated websites efficiently, please register for our next set of Website Office Hours on Wednesday, September 16, at 4:00 p.m. (ET) or Thursday, September 17, at 12:00 p.m. (ET). The same content will be covered in both sessions.

We will open each 30-minute session with a short, live demonstration on navigating our popular affiliated websites for healthcare personnel, including our recently launched Getting Started: For the New Vaccinator web page. You can submit questions when you register or live on Zoom during the session.

Register today for Immunize.org Website Office Hours (content is the same for both):

• Wednesday, September 16, at 4:00 p.m. (ET)
• Thursday, September 17, at 12:00 p.m. (ET)

The archive of previous Website Office Hours content is posted at Immunize.org’s "Webinars & Videos" page. Shorter, demonstration-only recordings of previous Website Office Hours are also available in our Website Training Videos series.

Mark your calendar for future Immunize.org Website Office Hours.